Ross Mitchell named artificial intelligence officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ross Mitchell has joined Moffitt Cancer Center as the artificial intelligence officer.

In this new role, he will lead the cancer center’s efforts to develop digital tools and technologies that utilize computer science to improve the efficiency and quality of cancer care.

Mitchell is also a senior member of Moffitt’s Department of Biostatistics and Bioinformatics and will collaborate with fellow research faculty to optimize projects utilizing artificial intelligence applications.

“Data science is a growing area in cancer research and care. Through the analysis of data, we can better predict outcomes to assist with informed decision-making. Mitchell will help Moffitt identify those business and clinical opportunities where predictive analytics, machine learning and other advanced technologies can be used to improve our patient experience,” said Dana Rollison, vice president, chief data officer and associate center director of Data Science at Moffitt. “He will also bring this skillset to our research enterprise.”

Mitchell comes to Moffitt from the Mayo Clinic in Scottsdale, where he led multiple medical imaging informatics initiatives such as the application of machine learning in brain tumor imaging.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login